scholarly journals Inferior vena cava filters in the management of cancer-associated venous thromboembolism: a systematic review

10.4081/59 ◽  
2011 ◽  
Vol 4 (3) ◽  
Author(s):  
Rachna Raman ◽  
Philip D. Leming ◽  
Manish Bhandari ◽  
Daniel Long ◽  
Michael B. Streiff
2010 ◽  
Vol 4 (3) ◽  
pp. 147-157 ◽  
Author(s):  
Rachna Raman ◽  
Philip D. Leming ◽  
Manish Bhandari ◽  
Daniel Long ◽  
Michael B. Streiff

2019 ◽  
Vol 16 (5) ◽  
pp. S214-S226 ◽  
Author(s):  
Jeet Minocha ◽  
Aaron M. Smith ◽  
Baljendra S. Kapoor ◽  
Nicholas Fidelman ◽  
Thomas R. Cain ◽  
...  

2016 ◽  
Vol 9 (3) ◽  
pp. 102-105 ◽  
Author(s):  
Lodewyk E Du Plessis ◽  
Ben W Mol ◽  
John M Svigos

Background Pregnant women with venous thromboembolism are traditionally managed with anticoagulation, but inferior vena cava filters are an alternative. We balanced risks and benefits of an inferior vena cava filter in a decision analysis. Methods We constructed a decision model to compare in pregnant women with VTE the outcome of (1) inferior vena cava filter and anticoagulant treatment versus (2) anticoagulant treatment only. Results Assuming a 63% risk reduction from an inferior vena cava filter (baseline mortality rate of venous thromboembolism of 0.5%), 318 women would need to be treated with inferior vena cava filters to prevent one venous thromboembolism related maternal death. Sensitivity analyses indicated that at a mortality rate of 0.5% the risk reduction from inferior vena cava filters needed to be 80%, while at a mortality rate of 2% a risk reduction of 20% would justify inferior vena cava filters. Conclusions In view of their potential morbidity, inferior vena cava filters should be restricted to pregnant woman at strongly increased risk of recurrent venous thromboembolism.


JAMA ◽  
2019 ◽  
Vol 321 (10) ◽  
pp. 1007
Author(s):  
Tobias Tritschler ◽  
Noémie Kraaijpoel ◽  
Philip S. Wells

Sign in / Sign up

Export Citation Format

Share Document